BCR and neoplasm: Twenty tumor‐bearing mice were randomly divided into four groups and treated every other day with 20 × 10−3m Tris‐HCl (control) and Bcr/Abl‐R6, PMIBcr/Abl‐R6 or imatinib at a dose of 5 mg Kg−1 by intraperitoneal injection (Figure9A).